Trident Lifeline

{
  "main_header": {
    "sid": 1003715,
    "name": "Trident Lifeline",
    "stock_name": "Trident Lifeline",
    "full_name": "Trident Lifeline Ltd",
    "name_url": "stocks-analysis/trident-lifeline",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "245.35",
    "chg": -0.35,
    "chgp": "-0.14%",
    "dir": -1,
    "prev_price": "245.70",
    "mcapval": "293.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 543616,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE0MKA01014",
    "curr_date": "Mar 20",
    "curr_time": "",
    "bse_nse_vol": 42600,
    "exc_status": "Active",
    "traded_date": "Mar 20, 2026",
    "traded_date_str": "2026 03 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/trident-lifeline-1003715-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Trident Lifeline Ltd Gains 1.85%: Valuation Shifts and Mixed Signals Shape Weekly Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/trident-lifeline-ltd-gains-185-valuation-shifts-and-mixed-signals-shape-weekly-performance-3905082",
        "imagepath": "",
        "date": "2026-03-21 11:03:28",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>16 Mar:</strong> Stock hits 52-week low of Rs.235.1 amid mixed financial results</p>\n                    <p><strong>16 Mar:</strong> Valuation metrics shift to more attractive levels despite sector headwinds</p>\n                    <p><strong>18 Mar:</strong> Stock rallies 3.61% to Rs.246.50, outperforming Sensex gains</p>\n                    <p><strong>20 Mar:</strong> Week closes at Rs.245.25, up 1.85% for the week versus Sensex decline</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.240.80</div></div>\n                    <div class=\"stat-item\"><div cl..."
      },
      {
        "title": "Trident Lifeline Ltd Falls to 52-Week Low of Rs.235.1 Amidst Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/trident-lifeline-ltd-falls-to-52-week-low-of-rs2351-amidst-mixed-financial-signals-3894310",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/TridentLifeline_priceRelatedfactors_3894310.png",
        "date": "2026-03-16 15:15:47",
        "description": "Trident Lifeline Ltd, a player in the Pharmaceuticals & Biotechnology sector, touched a new 52-week low of Rs.235.1 today, marking a significant price level after a prolonged period of decline. This fresh low comes amid broader market volatility and sector-specific headwinds, reflecting a challenging phase for the micro-cap company."
      },
      {
        "title": "Trident Lifeline Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/trident-lifeline-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-3892679",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/TridentLifeline_valuationdot_3892679.png",
        "date": "2026-03-16 08:01:25",
        "description": "Trident Lifeline Ltd has recently undergone a notable shift in its valuation parameters, moving from a fair to an attractive rating. This change is underscored by a significant recalibration of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the micro-cap pharmaceutical and biotechnology company as a compelling consideration for investors seeking value in a volatile sector environment."
      },
      {
        "title": "Trident Lifeline Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/trident-lifeline-ltd-is-rated-sell-3892046",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/TridentLifeline_mojoScore_3892046.png",
        "date": "2026-03-15 10:10:32",
        "description": "Trident Lifeline Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook."
      },
      {
        "title": "Trident Lifeline Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/trident-lifeline-ltd-is-rated-sell-by-marketsmojo-3868805",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/TridentLifeline_mojoScore_3868805.png",
        "date": "2026-03-04 10:10:55",
        "description": "Trident Lifeline Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Trident Lifeline Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/trident-lifeline-ltd-is-rated-sell-3849184",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/TridentLifeline_mojoScore_3849184.png",
        "date": "2026-02-21 10:10:44",
        "description": "Trident Lifeline Ltd is rated Sell by MarketsMOJO, with this rating last updated on 09 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Trident Lifeline Ltd Falls 5.89%: Downgrade and Valuation Reset Shape Weekly Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/trident-lifeline-ltd-falls-589-downgrade-and-valuation-reset-shape-weekly-decline-3838917",
        "imagepath": "",
        "date": "2026-02-14 10:02:15",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>09 Feb:</strong> Stock opens at ₹296.40, downgrade announced</p>\n                    <p><strong>10 Feb:</strong> Mojo Grade downgraded to Sell; stock closes at ₹283.00 (-4.52%)</p>\n                    <p><strong>11 Feb:</strong> Sharp decline to ₹272.05 (-5.34%) amid technical weakness</p>\n                    <p><strong>12 Feb:</strong> Partial recovery to ₹279.00 (+2.55%) on increased volume</p>\n                    <p><strong>13 Feb:</strong> Week closes at ₹278.95 (-0.02%) with Sensex down 1.40%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.296.40</d..."
      },
      {
        "title": "Trident Lifeline Ltd Downgraded to Sell Amid Technical Weakness and Flat Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/trident-lifeline-ltd-downgraded-to-sell-amid-technical-weakness-and-flat-financials-3830158",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/TridentLifeline_mojoScore_3830158.png",
        "date": "2026-02-10 08:55:45",
        "description": "Trident Lifeline Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 9 February 2026. The downgrade reflects a combination of deteriorating technical indicators, a shift in valuation metrics, flat financial trends, and a reassessment of the company’s overall quality. This comprehensive analysis explores the four key parameters that triggered the rating change and what it means for investors."
      },
      {
        "title": "Trident Lifeline Ltd Valuation Shifts Signal Changing Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/trident-lifeline-ltd-valuation-shifts-signal-changing-market-sentiment-3829752",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/TridentLifeline_valuationdot_3829752.png",
        "date": "2026-02-10 08:03:34",
        "description": "Trident Lifeline Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. Despite a sharp 4.52% decline in its share price on 10 Feb 2026, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now suggest a more attractive entry point relative to its historical and peer averages. This article analyses the implications of these valuation changes and what they mean for investors navigating a challenging market environment."
      }
    ],
    "total": 135,
    "sid": "1003715",
    "stock_news_url": "https://www.marketsmojo.com/news/trident-lifeline-1003715"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
      "datetime": "18-Mar-2026",
      "details": "We wish to inform to the Exchange that TRIDENT MEDIQUIP LIMITED (TML) (CIN: U33309GJ2019PLC110421) a subsidiary company has made Private Placement of equity shares to other shareholders. Pursuant to the above allotment to other shareholders the shareholding of Trident Lifeline Limited in Trident Mediquip Limited stands at 57.10%. Further informed to the Exchange that Trident Lifeline Limited has made further Investment by acquiring an additional equity stake of 2.67% of TRIDENT MEDIQUIP LIMITED (TML) (CIN: U33309GJ2019PLC110421) a subsidiary company from existing shareholders of the Company. Pursuant to the above the shareholding of the company in Trident Mediquip Limited has increased from 57.10% to 59.77%.",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "16-Mar-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Hardik Desai Family Trust",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
      "datetime": "03-Mar-2026",
      "details": "We wish to inform to the Exchange that TRIDENT MEDIQUIP LIMITED (TML) (CIN: U33309GJ2019PLC110421) a subsidiary company has made Private Placement of equity shares to other shareholders. Pursuant to the above allotment to other shareholders the shareholding of Trident Lifeline Limited in Trident Mediquip Limited stands at 57.34%.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Trident Lifeline Ltd Gains 1.85%: Valuation Shifts and Mixed Signals Shape Weekly Performance

2026-03-21 11:03:28

Key Events This Week

16 Mar: Stock hits 52-week low of Rs.235.1 amid mixed financial results

16 Mar: Valuation metrics shift to more attractive levels despite sector headwinds

18 Mar: Stock rallies 3.61% to Rs.246.50, outperforming Sensex gains

20 Mar: Week closes at Rs.245.25, up 1.85% for the week versus Sensex decline

Week Open

Rs.240.80

Read full news article

Trident Lifeline Ltd Falls to 52-Week Low of Rs.235.1 Amidst Mixed Financial Signals

2026-03-16 15:15:47

Trident Lifeline Ltd, a player in the Pharmaceuticals & Biotechnology sector, touched a new 52-week low of Rs.235.1 today, marking a significant price level after a prolonged period of decline. This fresh low comes amid broader market volatility and sector-specific headwinds, reflecting a challenging phase for the micro-cap company.

Read full news article

Trident Lifeline Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

2026-03-16 08:01:25

Trident Lifeline Ltd has recently undergone a notable shift in its valuation parameters, moving from a fair to an attractive rating. This change is underscored by a significant recalibration of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the micro-cap pharmaceutical and biotechnology company as a compelling consideration for investors seeking value in a volatile sector environment.

Read full news article

Trident Lifeline Ltd is Rated Sell

2026-03-15 10:10:32

Trident Lifeline Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Read full news article

Trident Lifeline Ltd is Rated Sell by MarketsMOJO

2026-03-04 10:10:55

Trident Lifeline Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Trident Lifeline Ltd is Rated Sell

2026-02-21 10:10:44

Trident Lifeline Ltd is rated Sell by MarketsMOJO, with this rating last updated on 09 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Trident Lifeline Ltd Falls 5.89%: Downgrade and Valuation Reset Shape Weekly Decline

2026-02-14 10:02:15

Key Events This Week

09 Feb: Stock opens at ₹296.40, downgrade announced

10 Feb: Mojo Grade downgraded to Sell; stock closes at ₹283.00 (-4.52%)

11 Feb: Sharp decline to ₹272.05 (-5.34%) amid technical weakness

12 Feb: Partial recovery to ₹279.00 (+2.55%) on increased volume

13 Feb: Week closes at ₹278.95 (-0.02%) with Sensex down 1.40%

Week Open

Rs.296.40Read full news article

Trident Lifeline Ltd Downgraded to Sell Amid Technical Weakness and Flat Financials

2026-02-10 08:55:45

Trident Lifeline Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 9 February 2026. The downgrade reflects a combination of deteriorating technical indicators, a shift in valuation metrics, flat financial trends, and a reassessment of the company’s overall quality. This comprehensive analysis explores the four key parameters that triggered the rating change and what it means for investors.

Read full news article

Trident Lifeline Ltd Valuation Shifts Signal Changing Market Sentiment

2026-02-10 08:03:34

Trident Lifeline Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. Despite a sharp 4.52% decline in its share price on 10 Feb 2026, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now suggest a more attractive entry point relative to its historical and peer averages. This article analyses the implications of these valuation changes and what they mean for investors navigating a challenging market environment.

Read full news article

View All News